• Explore /
  • Poster
  • / A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

Abstract Poster

Authors

null

Sharif S. Khan

Saint Francis Hospital, Inc, Greenville, SC

Sharif S. Khan , Shahram Mori , Deepa Jeyakumar , Michael Kenneth Keng , Hemant S. Murthy , Michal Bar-Natan , Krishna Gundabolu , Kristen M. O'Dwyer , Tulio Rodriguez , Anthony Selwyn Stein , Wendy Stock , Caspian Oliai , Christopher McCann , Faraz Zaman , Gerhard Zugmaier , Paul Gordon , Timothy S. Pardee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT04506086

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS7051)

DOI

10.1200/JCO.2021.39.15_suppl.TPS7051

Abstract #

TPS7051

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Tara L. Kaufmann

First Author: Gun-Dong Lee

First Author: Vinay Nittur

First Author: Charles Georges Parnot